SABS vs TLSI
SABS: SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1 diabetes. TLSI: TriSalus is a medical technology company integrating proprietary pressure-enabled drug delivery devices with immunotherapeutics to improve outcomes for patients with liver and pancreatic cancer.
Side-by-side fundamentals
| Metric | SABS | TLSI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.58 | $4.24 | |
| Market cap as of 2026-07-23 | $278M | $267M | |
| P/E as of 2026-07-23 | 20.97 | n/a | |
| PEG as of 2026-07-23 | n/a | -0.12 | |
| Net margin as of 2026-07-23 | -1795.8% | -60.9% | TLSI higher |
| Gross margin as of 2026-07-23 | n/a | +85.1% | |
| Operating margin as of 2026-07-23 | -2388.9% | -62.5% | TLSI higher |
| ROE as of 2026-07-23 | +15.2% | +12.0% | SABS higher |
| ROA as of 2026-07-23 | +12.5% | -59.4% | SABS higher |
| Debt / equity as of 2026-07-23 | 0.01 | 2.58 | SABS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +39.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +53.9% | |
| Beta as of 2026-07-23 | 0.56 | 0.40 | |
| 1-year return as of 2026-07-22 close | +34.8% | -5.0% | SABS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.